The medical world is carefully watching progress of Trontinemab, a investigational treatment showing remarkable results in initial clinical trials . This medication targets toxic tau , a key hallmark of the condition, considered to be arguably connected to cognitive decline than amyloid deposits that often received primary emphasis. While challenge